Back to News
Dec 9, 2025 4:00 PM

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder

Novartis AG (NYSE:NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

In August, Novartis shared topline results from the VAYHIT2 trial.

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45%, based on the primary endpoint of time to treatment failure (TTF), which assesses how long patients maintain safe platelet levels during and after the treatment period.

The median time to treatment ...